Raj Rajagovindan
Vice President, Translational Medicine Voyager Therapeutics, Inc
Seminars
Tuesday 3rd February 2026
Panel Discussion: Deciphering the Landscape of Emerging Neurodegenerative Fluid Markers Beyond p-tau & α-Synuclein
9:00 am
- GBA, LRRK2, and TREM2: Where do these emerging targets stand in terms of measurable, scalable biomarkers?
- What should define a ‘clinically useful’ biomarker when translatability remains uncertain?
- How do we ensure fluid biomarkers reflect causal disease biology rather than downstream noise?
